Feng J Z, Feng X H, Schneeweiss A
Guangdong Provincial Cardiovascular Institute, Guangzhou, People's Republic of China.
Am J Cardiol. 1990 Jun 4;65(21):32J-35J. doi: 10.1016/0002-9149(90)91308-s.
The anti-ischemic efficacy of isosorbide-5-mononitrate, 20 mg 3 times daily, on silent myocardial ischemia after myocardial infarction was studied in 28 Chinese patients with use of 48 hours of ambulatory electrocardiographic monitoring in a randomized, crossover, single-blind, placebo-controlled study. Isosorbide mononitrate reduced both painful and painless episodes of ischemia compared with placebo. The number of total ischemic episodes was reduced 88%, duration of ischemia 94%, time-ischemia integral 95%, and total maximal ST-segment depression 86% (p less than 0.01). The drug did not alter the heart rate and blood pressure, and had no evident adverse effect. Thus, isosorbide mononitrate is effective and well tolerated in postinfarction patients with silent ischemia.
在一项随机、交叉、单盲、安慰剂对照研究中，对28例中国患者使用动态心电图监测48小时，研究了每日3次、每次20毫克的单硝酸异山梨酯对心肌梗死后无症状心肌缺血的抗缺血疗效。与安慰剂相比，单硝酸异山梨酯减少了缺血的疼痛和无痛发作。总缺血发作次数减少88%，缺血持续时间减少94%，缺血时间积分减少95%，最大ST段总压低减少86%（P<0.01）。该药物未改变心率和血压，且无明显不良反应。因此，单硝酸异山梨酯对心肌梗死后无症状缺血患者有效且耐受性良好。
